Trials / Suspended
SuspendedNCT01305148
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
- Status
- Suspended
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 3,800 (estimated)
- Sponsor
- Iverson Genetic Diagnostics, Inc. · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The WARFARIN Study is a clinical trial designed to determine if the use of genetic information related to warfarin sensitivity can help create a dose of warfarin that will result in less hospitalizations and deaths related to warfarin.
Conditions
- Anti-coagulation Therapy
- DVT
- Pulmonary Embolism
- Joint Surgery Multiple
- Atrial Fibrillation
- Prosthetic Replacement of Mitral Valve
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Warfarin GenoSTAT Test | Use of genetic information from the GenoSTAT test to determine the warfarin dose |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2011-02-28
- Last updated
- 2015-08-31
Locations
56 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01305148. Inclusion in this directory is not an endorsement.